Cellular reprogramming allows generation of autologous hematopoietic progenitors from AML patients that are devoid of patient-specific genomic aberrations

Stem Cells

Volumn 33, Issue 6, 2015, Pages 1839-1849

  Salci, Kyle R ^a,b   Lee, Jong Hee ^a   Laronde, Sarah ^a   Dingwall, Steve ^a,b   Kushwah, Rahul ^a   Fiebig Comyn, Aline ^a   Leber, Brian ^b   Foley, Ronan ^b   Dal Cin, Arianna ^c   Bhatia, Mickie ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Acute myeloid leukemia; Chromosome aberrations; Hematopoietic progenitor cells; Human induced pluripotent stem cells; Reprogramming

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL POPULATION; CFU COUNTING; CONTROLLED STUDY; FIBROBLAST CULTURE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENOMICS; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NUCLEAR REPROGRAMMING; SKIN FIBROBLAST; TERATOMA; BONE MARROW; CANCER STEM CELL; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN GENOME; IMMUNOLOGY; INDUCED PLURIPOTENT STEM CELL; LEUKEMIA, MYELOID, ACUTE; PHYSIOLOGY;

BONE MARROW; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; GENOME, HUMAN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA, MYELOID, ACUTE; NEOPLASTIC STEM CELLS;

EID: 84929746565     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1994     Document Type: Article

References (61)

1. Lowenberg B, Downing JR, Burnett A,. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
2. Perl AE, Carroll M,. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr Treat Options Oncol 2007; 8: 265-276.
3. Vardiman JW, Thiele J, Arber DA, et al., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
4. Grimwade D, Walker H, Oliver F, et al., The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
5. Burnett A, Wetzler M, Lowenberg B,. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
6. Tallman MS, Gilliland DG, Rowe JM,. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
7. Shipley JL, Butera JN,. Acute myelogenous leukemia. Exp Hematol 2009; 37: 649-658.
8. Burnett AK, Goldstone AH, Stevens RM, et al., Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
9. Alvarnas JC, Forman SJ,. Graft purging in autologous bone marrow transplantation: A promise not quite fulfilled. Oncology (Williston Park) 2004; 18: 867-876; discussion 876-868, 881, 884.
10. Hagenbeek A, Martens AC,. Reinfusion of leukemic cells with the autologous marrow graft: Preclinical studies on lodging and regrowth of leukemia. Leuk Res 1985; 9: 1389-1395.
11. Linker CA,. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003; 31: 731-738.
12. Brenner MK, Rill DR, Moen RC, et al., Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
13. Hodby K, Pamphilon D,. Concise review: Expanding roles for hematopoietic cellular therapy and the blood transfusion services. Stem Cells 2011; 29: 1322-1326.
14. Copelan EA,. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
15. Li JM, Giver CR, Lu Y, et al., Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy 2009; 1: 599-621.
16. Bishop MR,. Hematopoietic stem cell transplantation. Introduction. Cancer Treat Res 2009; 144: ix-x.
17. Kelly SS, Parmar S, De Lima M, et al., Overcoming the barriers to umbilical cord blood transplantation. Cytotherapy 2010; 12: 121-130.
18. Takahashi K, Tanabe K, Ohnuki M, et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
19. Park IH, Zhao R, West JA, et al., Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451: 141-146.
20. Aasen T, Raya A, Barrero MJ, et al., Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26: 1276-1284.
21. Eminli S, Utikal J, Arnold K, et al., Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 2008; 26: 2467-2474.
22. Yu J, Vodyanik MA, Smuga-Otto K, et al., Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
23. Risueno RM, Sachlos E, Lee JH, et al., Inability of human induced pluripotent stem cell-hematopoietic derivatives to downregulate microRNAs in vivo reveals a block in xenograft hematopoietic regeneration. Stem Cells 2012; 30: 131-139.
24. Wang L, Menendez P, Shojaei F, et al., Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 2005; 201: 1603-1614.
25. Suzuki N, Yamazaki S, Yamaguchi T, et al., Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. Mol Ther 2013; 21: 1424-1431.
26. Amabile G, Welner RS, Nombela-Arrieta C, et al., In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 2013; 121: 1255-1264.
27. Doulatov S, Vo LT, Chou SS, et al., Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell 2013; 13: 459-470.
28. Choi KD, Vodyanik M, Slukvin, II,. Hematopoietic differentiation and production of mature myeloid cells from human pluripotent stem cells. Nat Protoc 2011; 6: 296-313.
29. Choi KD, Yu J, Smuga-Otto K, et al., Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009; 27: 559-567.
30. Cerdan C, Rouleau A, Bhatia M,. VEGF-A165 augments erythropoietic development from human embryonic stem cells. Blood 2004; 103: 2504-2512.
31. Chadwick K, Wang L, Li L, et al., Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 2003; 102: 906-915.
32. Villegas J, McPhaul M,. Establishment and culture of human skin fibroblasts. Curr Protoc Mol Biol 2005;Chapter 28:Unit 28 23.
33. Hong SH, Werbowetski-Ogilvie T, Ramos-Mejia V, et al., Multiparameter comparisons of embryoid body differentiation toward human stem cell applications. Stem Cell Res 2010; 5: 120-130.
34. Menendez P, Catalina P, Rodriguez R, et al., Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 2009; 206: 3131-3141.
35. Schoch C, Schnittger S, Klaus M, et al., AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102: 2395-2402.
36. Giagounidis AA, Germing U, Aul C,. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006; 12: 5-10.
37. Bains A, Lu G, Yao H, et al., Molecular and clinicopathologic characterization of AML with isolated trisomy 4. Am J Clin Pathol 2012; 137: 387-394.
38. Marlton P, Keating M, Kantarjian H, et al., Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995; 9: 965-971.
39. Paulsson K, Johansson B,. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol (Paris) 2007; 55: 37-48.
40. Ratnam KV, Su WP, Ziesmer SC, et al., Value of immunohistochemistry in the diagnosis of leukemia cutis: Study of 54 cases using paraffin-section markers. J Cutan Pathol 1992; 19: 193-200.
41. Hook EB,. Exclusion of chromosomal mosaicism: Tables of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29: 94-97.
42. Hong SH, Lee JH, Lee JB, et al., ID1 and ID3 represent conserved negative regulators of human embryonic and induced pluripotent stem cell hematopoiesis. J Cell Sci 2011; 124: 1445-1452.
43. Boyer LA, Lee TI, Cole MF, et al., Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-956.
44. Adewumi O, Aflatoonian B, Ahrlund-Richter L, et al., Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007; 25: 803-816.
45. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al., Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
46. Bershteyn M, Hayashi Y, Desachy G, et al., Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. Nature 2014; 507: 99-103.
47. Hussein SM, Batada NN, Vuoristo S, et al., Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471: 58-62.
48. Moore MA, Spitzer G, Williams N, et al., Agar culture studies in 127 cases of untreated acute leukemia: The prognostic value of reclassification of leukemia according to in vitro growth characteristics. Blood 1974; 44: 1-18.
49. Bain BJ, Clark DM, Wilkins BS,. Bone Marrow Pathology. Oxford: Wiley, 2010.
50. Schnerch A, Lee JB, Graham M, et al., Human embryonic stem cell-derived hematopoietic cells maintain core epigenetic machinery of the polycomb group/Trithorax Group complexes distinctly from functional adult hematopoietic stem cells. Stem Cells Dev 2013; 22: 73-89.
51. McIntyre BA, Ramos-Mejia V, Rampalli S, et al., Gli3-mediated hedgehog inhibition in human pluripotent stem cells initiates and augments developmental programming of adult hematopoiesis. Blood 2013; 121: 1543-1552.
52. Kushwah R, Guezguez B, Lee JB, et al., Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human. EMBO Rep 2014; 15: 1128-1138.
53. Gupta V, Lazarus HM, Keating A,. Myeloablative conditioning regimens for AML allografts: 30 years later. Bone Marrow Transplant 2003; 32: 969-978.
54. Kazenwadel J, Secker GA, Liu YJ, et al., Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012; 119: 1283-1291.
55. Pabst T, Eyholzer M, Haefliger S, et al., Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008; 26: 5088-5093.
56. Greaves M,. In utero origins of childhood leukaemia. Early Hum Dev 2005; 81: 123-129.
57. Zuna J, Burjanivova T, Mejstrikova E, et al., Covert preleukemia driven by MLL gene fusion. Genes Chromosomes Cancer 2009; 48: 98-107.
58. Brain JM, Goodyer N, Laneuville P,. Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction. Cancer Res 2003; 63: 4895-4898.
59. Hong D, Gupta R, Ancliff P, et al., Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-339.
60. Jan M, Snyder TM, Corces-Zimmerman MR, et al., Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra118.
61. Shlush LI, Zandi S, Mitchell A, et al., Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014; 506: 328-333.